Valeant Pharmaceuticals International Inc.'s (TSE:VRX) U.S.-listed stock fell about 10 percent in premarket trading on Thursday after the Wall Street Journal reported that prosecutors had opened a criminal investigation into the Canadian drugmaker.
Valeant Pharmaceuticals International Inc. cut its 2016 profit forecast as new Chief Executive Officer Joseph Papa starts his attempt to turn around the embattled drugmaker. The shares plummeted in early trading.
Valeant Pharmaceuticals International Inc. (TSE:VRX) received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.
LAVAL, Que. — Embattled drug company Valeant Pharmaceuticals International Inc. has named Joseph Papa as its new chairman and chief executive.
The company says Papa, who was chairman and CEO of drug company Perrigo in the U.S., is expected to join Valeant early next month.
